Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00241007 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 836
- Enrollment target
NCT00241007: Completed Phase 3 study, sponsored by Novartis.
NCT00241007 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 836 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00241007, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 836 participants
- Enrollment target
Study Summary
SAFETY EXTENSION STUDY TO THE CORE STUDY CVAH631C2301
Interventions
- DRUG VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 836 participants |
| Start Date | 2003-12 |
| Est. Completion | 2005-03 |
| Phase | Phase 3 |
What the finished NCT00241007 record still lists
NCT00241007 is an interventional study that assigns participants to a tested intervention. The registered 836 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE is the first listed.
NCT00241007 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00241007 about?
NCT00241007 is a clinical study titled "A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension". SAFETY EXTENSION STUDY TO THE CORE STUDY CVAH631C2301
What is the current status of trial NCT00241007?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 836 participants. The study started on 2003-12. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00241007?
The interventions under investigation include: VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE (DRUG).
Who is sponsoring clinical trial NCT00241007?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00241007's enrollment target sits among peer trials
836 396th of 2000 higher than 1,604 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02118467 · 836 participants · Phase 4
Vasoactive Drugs in Intensive Care Unit
- NCT02422550 · 837 participants
Imaging Acquisition and Analysis Methods for Optimization of MRI Radiation Oncology Simulation and Response Assessment
- NCT03670524 · 835 participants · NA
Health, Environment and Action in Louisville (HEAL) Green Heart Louisville Project
- NCT04831580 · 840 participants · NA
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia